89bio, Inc. Profile Avatar - Palmy Investing

89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…

Biotechnology
US, San Francisco [HQ]

Risk Factors

By Management
10-K
  1. We rely on third parties for certain aspects of our product candidate development process and we may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates and our business could be substantially harmed.

  2. We have received breakthrough therapy designation for pegozafermin in NASH from the FDA, but such designation may not actually lead to a faster development or regulatory review or approval process. In addition, we may seek breakthrough therapy designation for other indications or future product candidates, but we might not receive such designation.

  3. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our stock may decrease.

Get PRO Today.

Read 22 more risk factors of 89bio, Inc.

End of ETNB's Analysis
CIK: 1785173 CUSIP: 282559103 ISIN: US2825591033 LEI: - UEI: -
Secondary Listings
ETNB has no secondary listings inside our databases.